Keyphrases
Acute Myeloid Leukemia
76%
Venetoclax
62%
Newly Diagnosed
21%
Hypomethylating Agents
18%
Induction Chemotherapy
13%
FLAG-Ida
12%
Acute Lymphoblastic Leukemia
12%
Isocitrate Dehydrogenase 1 (IDH1)
11%
Intensive Chemotherapy
11%
Overall Survival
10%
Older Patients
10%
European LeukemiaNet
9%
Complete Remission
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
8%
Azacitidine
8%
Risk Stratification
8%
Survival Prognostication
7%
Leukemia Patients
7%
Minimal Residual Disease
7%
Hematological Malignancies
7%
Treatment Landscape
7%
Clinical Outcomes
7%
Leukemia Therapy
7%
Induction Therapy
7%
Clonal Evolution
6%
Event-free Survival
6%
Nucleophosmin 1 (NPM1)
6%
High-risk Myelodysplastic Syndrome
6%
Matched Cohort Study
6%
Consolidation Therapy
6%
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
6%
Clinical Application
6%
Transplant Outcomes
6%
Isocitrate Dehydrogenase Inhibitor
6%
Clinical Correlation
6%
Eosinophilic Dermatosis
6%
Clonal Hematopoiesis
6%
Anemia Diagnosis
6%
County Hospital
6%
Splicing mutation
6%
Propensity Score Matching
6%
Elderly Patients
6%
Hospital Systems
6%
Acute Myeloid
6%
Classification System
6%
Clonal Origin
6%
Ivosidenib
6%
Hematopoietic Stem Cell Transplantation
6%
Classification Scheme
6%
Bone Marrow
6%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Venetoclax
60%
Hypomethylating Agent
26%
Overall Survival
20%
Acute Myelogenous Leukemia
18%
Risk Stratification
14%
Induction Chemotherapy
14%
Acute Lymphoblastic Leukemia
12%
Prognostication
10%
Minimal Residual Disease
10%
Targeted Therapy
9%
Cohort Analysis
8%
Azacitidine
8%
Molecularly Targeted Therapy
8%
Transplantation
8%
Myelodysplastic Syndrome
8%
Allotransplantation
7%
Event Free Survival
7%
Isocitrate Dehydrogenase Inhibitor
7%
Clinical Trial
7%
NPM1
6%
Hematopoiesis
6%
Eosinophilic
6%
Ivosidenib
6%
Enasidenib
6%
Spliceosome
6%
Plasmacytoid Dendritic Cell
6%
Elderly Patient
6%
Aplastic Anemia
6%
Lymphocytic Lymphoma
6%
Hematopoietic Stem Cell Transplantation
6%
Cancer
6%
Dermatosis
6%
Neoplasm
6%
Asparaginase
6%
Thromboprophylaxis
6%
Cytarabine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
72%
Venetoclax
68%
Overall Survival
19%
Remission
18%
Azacitidine
18%
Ivosidenib
18%
Chemotherapy
14%
Enasidenib
12%
Acute Lymphoblastic Leukemia
12%
Leukemogenesis
8%
Disease
8%
Minimal Residual Disease
8%
Isocitrate Dehydrogenase 1
7%
Syndrome
7%
Isocitrate Dehydrogenase Inhibitor
7%
Isocitrate Dehydrogenase
7%
Leukemia
7%
Cohort Study
7%
Hematologic Malignancy
7%
Event Free Survival
6%
Myelodysplastic Syndrome
6%
CCAAT Enhancer Binding Protein Alpha
6%
Oxidoreductase
6%
Asparaginase
6%
Enoxaparin
6%
Adverse Event
6%